ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
Acurx Pharmaceuticals (Nasdaq: ACXP) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The event will be held both in-person at the Lotte New York Palace Hotel in New York City and virtually, featuring over 550 company presentations.
David P. Luci, President & CEO of Acurx Pharmaceuticals, will provide an overview of the company's business during the presentation. Institutional investors can register for the conference through the provided link to access the company presentations and panels, which will be available on-demand starting September 9 at 7:00 A.M. (ET).
Acurx Pharmaceuticals (Nasdaq: ACXP) ha annunciato la sua partecipazione al 26° Congresso Globale di Investimenti Annuale H.C. Wainwright, in programma dal 9 all'11 settembre 2024. L'evento si svolgerà sia in presenza presso il Lotte New York Palace Hotel a New York City che in modalità virtuale, con oltre 550 presentazioni aziendali.
David P. Luci, Presidente e CEO di Acurx Pharmaceuticals, fornirà una panoramica del business dell'azienda durante la presentazione. Gli investitori istituzionali possono registrarsi per la conferenza tramite il link fornito per accedere alle presentazioni e ai panel aziendali, che saranno disponibili on-demand a partire dal 9 settembre alle 7:00 A.M. (ET).
Acurx Pharmaceuticals (Nasdaq: ACXP) ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright, programada del 9 al 11 de septiembre de 2024. El evento se llevará a cabo tanto en persona en el Lotte New York Palace Hotel en Nueva York como virtualmente, con más de 550 presentaciones de empresas.
David P. Luci, Presidente y CEO de Acurx Pharmaceuticals, ofrecerá una visión general del negocio de la compañía durante la presentación. Los inversores institucionales pueden registrarse para la conferencia a través del enlace proporcionado para acceder a las presentaciones y paneles de la empresa, que estarán disponibles bajo demanda a partir del 9 de septiembre a las 7:00 A.M. (ET).
Acurx Pharmaceuticals (Nasdaq: ACXP)는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참가한다고 발표했습니다. 이 회의는 2024년 9월 9일부터 11일까지 진행될 예정이며, 뉴욕시의 Lotte New York Palace Hotel에서 대면 방식으로 개최되고, 가상으로도 참여할 수 있어 550개 이상의 회사 발표가 포함됩니다.
Acurx Pharmaceuticals의 대통령이자 CEO인 David P. Luci는 발표 중에 회사 사업에 대한 개요를 제공할 것입니다. 기관 투자자는 제공된 링크를 통해 회의에 등록할 수 있으며, 이는 9월 9일 오전 7시(ET)부터 주문형으로 제공될 회사 발표 및 패널에 접근할 수 있게 됩니다.
Acurx Pharmaceuticals (Nasdaq: ACXP) a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright, prévue du 9 au 11 septembre 2024. L'événement se tiendra à la fois en personne à l'hôtel Lotte New York Palace à New York et virtuellement, avec plus de 550 présentations d'entreprises.
David P. Luci, Président et Directeur Général d'Acurx Pharmaceuticals, présentera un aperçu des activités de l'entreprise lors de la présentation. Les investisseurs institutionnels peuvent s'inscrire à la conférence via le lien fourni pour accéder aux présentations et aux panels de l'entreprise, qui seront disponibles à la demande à partir du 9 septembre à 7h00 (ET).
Acurx Pharmaceuticals (Nasdaq: ACXP) hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben, die für den 9. bis 11. September 2024 geplant ist. Die Veranstaltung findet sowohl persönlich im Lotte New York Palace Hotel in New York City als auch virtuell statt und umfasst über 550 Unternehmenspräsentationen.
David P. Luci, Präsident und CEO von Acurx Pharmaceuticals, wird während der Präsentation einen Überblick über das Geschäft des Unternehmens geben. Institutionelle Investoren können sich über den bereitgestellten Link zur Konferenz anmelden, um auf die Unternehmenspräsentationen und -panels zuzugreifen, die ab dem 9. September um 7:00 Uhr (ET) auf Abruf verfügbar sein werden.
- None.
- None.
September 9-11, 2024
The in-person venue for the event is the Lotte New York Palace Hotel in
David P. Luci, President & CEO of the Company, will provide an overview of the Company's business during the presentation.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference. Over 550 corporate presentations & panels are available during September 9-11, 2024.
Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024
Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person location date/time at the Lotte New York Palace Hotel,
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2023, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & Chief Executive Officer
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-announces-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-302229628.html
SOURCE Acurx Pharmaceuticals, Inc.
FAQ
When is Acurx Pharmaceuticals (ACXP) presenting at the H.C. Wainwright Global Investment Conference?
Where is the H.C. Wainwright Global Investment Conference being held for Acurx Pharmaceuticals (ACXP)?
Who will be presenting on behalf of Acurx Pharmaceuticals (ACXP) at the H.C. Wainwright conference?
How can investors access Acurx Pharmaceuticals' (ACXP) presentation at the H.C. Wainwright conference?
